Interim Analysis of Phase 2 Results for Cemiplimab in Patients with Metastatic Basal Cell Carcinoma (mBCC) who Progressed on or are Intolerant to Hedgehog Inhibitors (HHIs). SKIN The Journal of Cutaneous Medicine, [S. l.], v. 5, n. 1, p. s3, 2021. DOI: 10.25251/skin.5.supp.3. Disponível em: https://skin.dermsquared.com/skin/article/view/1155. Acesso em: 19 apr. 2025.